Plain-English translation of NCT06914544 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
The HYPOSTAT-III trial is testing a new approach called hypofractionated radiosurgery for men with localized prostate cancer. Instead of spreading radiation treatment over many weeks, this treatment delivers focused, high-dose radiation in just three sessions. The goal is to treat the cancer effectively while potentially reducing side effects and treatment time compared to traditional radiation schedules.
Standard radiation therapy for prostate cancer typically requires many weeks of treatment, which can be inconvenient and burden patients' lives. This trial is designed to see whether delivering the same total radiation dose in fewer, more intensive sessions works just as well while being more convenient for patients.
You likely qualify if…
You likely don't qualify if…
You would receive three radiation treatments over a short period, with each session delivering a high dose of focused radiation to your prostate. You'll visit the clinic at baseline for planning, then on each of the three treatment days, and finally for four follow-up visits at 4–6 weeks, 3 months, 6 months, and one year after your last treatment. The entire active treatment phase takes just days to weeks, though you'll be monitored for a full year afterward to track how well the treatment worked and to watch for any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Germany